{"title":"JAK1/2抑制剂会改变骨髓纤维化的治疗标准吗?","authors":"Chul Won Jung","doi":"10.5045/kjh.2012.47.4.241","DOIUrl":null,"url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://dx.doi.org/10.5045/kjh.2012.47.4.241 The Korean Journal of Hematology Volume 47ᆞNumber 4ᆞDecember 2012","PeriodicalId":23001,"journal":{"name":"The Korean Journal of Hematology","volume":"47 4","pages":"241-2"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.241","citationCount":"1","resultStr":"{\"title\":\"Will JAK1/2 inhibitors change the standard of care for myelofibrosis?\",\"authors\":\"Chul Won Jung\",\"doi\":\"10.5045/kjh.2012.47.4.241\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://dx.doi.org/10.5045/kjh.2012.47.4.241 The Korean Journal of Hematology Volume 47ᆞNumber 4ᆞDecember 2012\",\"PeriodicalId\":23001,\"journal\":{\"name\":\"The Korean Journal of Hematology\",\"volume\":\"47 4\",\"pages\":\"241-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.5045/kjh.2012.47.4.241\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Korean Journal of Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5045/kjh.2012.47.4.241\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2012/12/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean Journal of Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/kjh.2012.47.4.241","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/12/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://dx.doi.org/10.5045/kjh.2012.47.4.241 The Korean Journal of Hematology Volume 47ᆞNumber 4ᆞDecember 2012
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
